Monitor for the appointment of a permanent CFO, which could signal strategic direction. The interim CFO arrangement is standard and does not indicate distress.
Price Chart
Executive Summary
Cadrenal Therapeutics appointed John P. Sharp as Interim CFO via a consulting agreement with Lohman & Associates at $455/hour for up to 24 hours/week, replacing Quang X. Pham. Director Steven Zelenkofske resigned amicably, and the board realigned its classes. These are routine governance changes with no financial or operational impact.
Key Facts
- John P. Sharp appointed Interim CFO effective June 25, 2026, replacing Quang X. Pham
- Sharp engaged via Lohman & Associates at $455/hour, up to 24 hours/week, with a $25,000 retainer
- Director Steven Zelenkofske resigned effective June 30, 2026, citing no disagreement
- Board realigned classes: Dr. Glynn Wilson moved from Class I to Class III
- Company is conducting a search for a permanent CFO
Financial Impact
No material financial impact; consulting fees are routine and immaterial relative to market cap
Risk Factors
- Prolonged interim CFO period may signal difficulty attracting a permanent candidate
- No financial data or guidance provided in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-073213 |
| Document: ea0296328-8k_cadrenal.htm | 0001213900-26-073213 |
| Document: ea029632801ex10-2.htm | 0001213900-26-073213 |
| Document: 0001213900-26-073213-index-headers.html | 0001213900-26-073213 |
| Document: 0001213900-26-073213-index.html | 0001213900-26-073213 |
| Document: 0001213900-26-073213.txt | 0001213900-26-073213 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | 8-K | $0.9723 | awaiting T+60 | — | $0.9100 (−6.41%) |
Aug 31, 2026 8w ago | 8-K | $1.75 | awaiting T+60 | — | $0.9100 (−48.00%) |
Jul 21, 2026 14w ago | 8-K | $2.17 $0.9970 | ▼ −54.06% | ▼ −58.03% | $0.9100 (−58.06%) |
Jul 21, 2026 14w ago | EFFECT | $2.17 $0.9970 | ▼ −54.06% | ▼ −58.03% | $0.9100 (−58.06%) |
Jul 1, 2026 17w ago | Press Release | $3.60 $1.12 | ▲ +68.89% | ▲ +71.94% | $0.9100 (+74.72%) |
Jun 29, 2026 17w ago | 8-K | $3.34 $1.32 | ▼ −60.48% | ▼ −64.04% | $0.9100 (−72.75%) |
Jun 18, 2026 18w ago | 8-K | $3.50 $1.06 | ▼ −69.71% | ▼ −71.61% | $0.9100 (−74.00%) |
Jun 15, 2026 19w ago | 144 | $3.04 $1.18 | ▲ +61.18% | ▲ +62.18% | $0.9100 (+70.07%) |
May 7, 2026 24w ago | Press Release | $6.02 $1.96 | ▼ −67.44% | ▼ −71.27% | $0.9100 (−84.88%) |
Apr 30, 2026 25w ago | 8-K | $6.67 $2.06 | ▼ −69.12% | ▼ −72.22% | $0.9100 (−86.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers